Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on X:
“Long-term follow-up is not the end of a clinical trial-it is where the real conversation begins.”
In this JAMA Oncology Editor’s Note, I reflect on the final results of the ASTRUM-005 trial, the clinical benefits achieved for patients with extensive-stage small cell lung cancer (ES-SCLC), and the important questions that remain unanswered.
Title: Durable Gains and Persistent Questions From the ASTRUM-005 Trial
Author: Narjusտ Florez
Read the full article on JAMA Oncology.
Other articles featuring Narjust Florez on OncoDaily.